Overview
The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.
Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Gavin Churchyard
AIDS Clinical Trials Group
Payam Nahid
Centers for Disease Control / TB Trials Consortium
Charles Wells
Gates Medical Research Institute
Joel Lilievre
GSK
Tine DeMarez
Janssen
Anil Koul
Johnson & Johnson
Marc Destito
Otsuka
Kiyean Nam
Qurient
Andreas Diacon
Stellenbosch University
Andreas Diacon
Stellenbosch University
Eugene Sun
TB Alliance
Michael Hoelscher
EDCTP/University of Munich
Nicholas Paton
SPRINT-TB
Meeting Recap
The 2019 WGND Annual Meeting and Reception took place on Tuesday, October 29th from 16:00 to 20:00 IST in the Pearl 3 Room at the Cyber Convention Centre. The meeting occurred in conjunction with the 50th Union World Conference on Lung Health in Hyderabad, India. During the meeting, updates were provided by representatives from:
- AIDS Clinical Trial Group
- US Centers for Disease Control / TB Trials Consortium
- Gates Medical Research Institute
- GlaxoSmithKline
- Janssen / Johnson & Johnson
- Ludwig-Maximilians University / PanACEA
- Otsuka Pharmaceuticals
- Qurient
- TASK Applied Science / Stellenbosch University
- TB Alliance
- TB Drug Pipeline UpdatesTB Drug Development Year-in-ReviewBarbara Laughonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/01_Year-in-Review_Barbara%20Laughon.pdfAIDS Clinical Trials GroupGavin Churchyardhttps://www.newtbdrugs.org/sites/default/files/meetings/files/02_AIDS%20Clinical%20Trial%20Group_Gavin%20Churchyard.pdfCenters for Disease Control / TB Trials ConsortiumPayam Nahidhttps://www.newtbdrugs.org/sites/default/files/meetings/files/03_CDC_TBTC_Payam%20Nahid%2012.18.2019.pdfGates Medical Research InstituteCharles Wellshttps://www.newtbdrugs.org/sites/default/files/meetings/files/04_Gates%20MRI_Charles%20Wells.pdfGlaxoSmithKlineDavid BarrosJanssenTine DeMarezhttps://www.newtbdrugs.org/sites/default/files/meetings/files/06_Janssen_Tine%20De%20Marez.pdfJohnson & JohnsonAnil KoulOtsukaMarc Destitohttps://www.newtbdrugs.org/sites/default/files/meetings/files/09_Otsuka_Marc%20Destito_updated.pdfQurient, Inc.Andreas DiaconTASK Applied Science / Stellenbosch UniversityAndreas DiaconTB AllianceEugene Sunhttps://www.newtbdrugs.org/sites/default/files/meetings/files/12_TB%20Alliance_Eugene%20Sun.pdfUniversity of Munich / PanACEAMichael Hoelscherhttps://www.newtbdrugs.org/sites/default/files/meetings/files/08_LMU-PanACEA_Michael%20Hoelscher-NHeinrich.pdfSPRINT TBNicholas Patonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/12b_NUSingapore_Nick%20Paton.pdf